Fundz

Pelage Pharmaceuticals Announces $16.75M Series A

PRIVATEFeb 27, 2024

Amount Raised

$16.8 Million

Round Type

Series A

Los AngelesBiotechnologyHealthcare

Investors

Yk Bio VenturesVisionary VenturesMain Street AdvisorsGV

Description

Pelage Pharmaceuticals raised $16.75M in Series A funding led by GV with participation from Main Street Advisors, Visionary Ventures, and YK BioVentures. The company plans to use the funds to advance a first-in-class treatment for androgenetic alopecia, pattern baldness, and other types of alopecia, including chemotherapy-induced hair loss.

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as Pelage Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.

  • RenovoRx raised $11M on April 11, 2024.
  • BioLineRx Ltd raised $20M (Pre-Seed) on April 10, 2024.
  • Enlaza Therapeutics raised $84M on April 5, 2024.
  • Corvex Legacy Holdings raised $24M (Seed) on April 2, 2024.
  • Pierrepont Therapeutics raised $2.1M (Seed) on April 2, 2024.
  • Corvex Legacy Holdings raised $24M on April 2, 2024.

Who to call at Pelage Pharmaceuticals, and when

A new round usually means Pelage Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Pelage Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Pelage Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Pelage Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Pelage Pharmaceuticals

Location

Los Angeles, California, United States

About

Pelage Pharmaceuticals is a clinical-stage regenerative medicine company developing first-in-class treatments for hair loss. With a focus on stem cell biology and metabolism, Pelage is advancing a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body’s ability to naturally grow hair. Its lead program, PP405, is currently in Phase 2a clinical trials. Through its rigorous scientific foundation, Pelage is pioneering first-in-class hair growth solutions for people of all hair types experiencing hair loss.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Pelage Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsDaniel G., Chief Executive OfficerSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Pelage Pharmaceuticals's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Pelage Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.